Theralase Technologies Inc (TLTFF)

[was CUIN2]

Canada Approves Next Generation TLC-2000 Therapeutic Laser
Accesswire
3 minutes ago
????
TORONTO, ON / ACCESSWIRE / December 14, 2015 / Theralase Technologies Inc. ("Theralase" or the "Company") (TLT:TSXV) (TLTFF:OTC), a leading biotechnology manufacturer focused on commercializing medical technologies to eliminate pain and destroy cancer, announced today that Health Canada has approved the next generation TLC-2000 Therapeutic Medical Laser System by issuing a Medical Device Licence.

Health Canada recently reviewed an application submitted by the Company and has determined that the TLC-2000 is eligible to be granted a Medical Device Licence in accordance with Medical Device Regulations, Section 36. and has authorized the Company to market and sell the device throughout Canada, effective immediately.

Roger Dumoulin-White, President and CEO, stated that, "The Company has focused its resources on the successful completion of four major strategic objectives prior to yearend; specifically:

- Health Canada approval of the next generation TLC-2000 Therapeutic Medical Laser System (completed)
- FDA approval of the TLC-2000 (completed)
- Review Ethics Board approval of a Phase Ib clinical trial for Theralase's anti-cancer technology for the treatment of Non-Muscle Invasive Bladder Cancer ("NMIBC")
- Health Canada approval to commence the Phase Ib clinical trial for NMIBC.
Theralase has now completed the first two of these four strategic objectives and is working on completing the remaining two prior to yearend."